Genistein: A Potential Natural Lead Molecule for New Drug Design and Development for Treating Memory Impairment

Fuloria, Shivkanya; Yusri, Muhamad Azrul Amir; Sekar, Mahendran; Gan, Siew Hua; Rani, Nur Najihah Izzati Mat; Lum, Pei Teng; Ravi, Subban; Subramaniyan, Vetriselvan; Ferdosh, Sahena; Jeyabalan, Srikanth; Wu, Yuan Seng; Meenakshi, Dhanalekshmi Unnikrishnan; Sathasivam, Kathiresan V.; Fuloria, Neeraj Kumar

doi:10.3390/molecules27010265

Cited by 24 publications

(25 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LS-TC-MNP was dissolved in methanol: water mixture. Then, it was diluted with sufficient quantity of mobile phase and was analyzed by HPLC according to the previously developed HPLC method by our research group [ 37 ]. The loading efficiency of LS in the LS-TC-MNP was then calculated using the Equation (3).…”

Section: Methodsmentioning

confidence: 99%

“…After predetermined time intervals (1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, and 48 h), 0.5 mL samples were removed from the arm of the receptor compartment and replaced with an equal volume of fresh phosphate buffer (pH 7.4) kept at 37 ± 1 °C. As reported earlier, samples were then analyzed by HPLC [ 37 ]. The in-vitro release profile was then subjected to mathematical modeling by using free DD Solver software (Microsoft Excel add-in).…”

Section: Methodsmentioning

confidence: 99%

“…After predetermined time intervals (1, 2, 3, 4, 6, 8, 12, 16, and 24 h), 500 µL of sample was drained and refilled with fresh buffer. The samples were then analyzed by HPLC [ 37 ].…”

Section: Methodsmentioning

confidence: 99%

“…Homogenate was soaked in methanol under stirring overnight to extract LS. The extract was filtered through 0.45 syringe filter and analyzed by HPLC [ 37 ].…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Thiolated Chitosan Microneedle Patch of Levosulpiride from Fabrication, Characterization to Bioavailability Enhancement Approach

et al. 2022

Self Cite

View full text Add to dashboard Cite

In this study, a first attempt has been made to deliver levosulpiride transdermally through a thiolated chitosan microneedle patch (TC-MNP). Levosulpiride is slowly and weakly absorbed from the gastrointestinal tract with an oral bioavailability of less than 25% and short half-life of about 6 h. In order to enhance its bioavailability, levosulpiride-loaded thiolated chitosan microneedle patches (LS-TC-MNPs) were fabricated. Firstly, thiolated chitosan was synthesized and characterized by nuclear magnetic resonance (1HNMR) spectroscopy, attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy, differential scanning calorimetry (DSC), and X-ray diffraction (XRD). Thiolated chitosan has been used in different drug delivery systems; herein, thiolated chitosan has been used for the transdermal delivery of LS. LS-TC-MNPs were fabricated from different concentrations of thiolated chitosan solution. Furthermore, the levosulpiride-loaded thiolated chitosan microneedle patch (LS-TC-MNP) was characterized by FTIR spectroscopic analysis, scanning electron microscopy (SEM) study, penetration ability, tensile strength, moisture content, patch thickness, and elongation test. LS-TC-MNP fabricated with 3% thiolated chitosan solution was found to have the best tensile strength, moisture content, patch thickness, elongation, drug-loading efficiency, and drug content. Thiolated chitosan is biodegradable, nontoxic and has good absorption and swelling in the skin. LS-TC-MNP-3 consists of 100 needles in 10 rows each with 10 needles. The length of each microneedle was 575 μm; they were pyramidal in shape, with sharp pointed ends and a base diameter of 200 µm. The microneedle patch (LS-TC-MNP-3) resulted in-vitro drug release of 65% up to 48 h, ex vivo permeation of 63.6%, with good skin biocompatibility and enhanced in-vivo pharmacokinetics (AUC = 986 µg/mL·h, Cmax = 24.5 µg/mL) as compared to oral LS dispersion (AUC = 3.2 µg/mL·h, Cmax = 0.5 µg/mL). Based on the above results, LS-TC-MNP-3 seems to be a promising strategy for enhancing the bioavailability of levosulpiride.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…After predetermined time intervals (1, 2, 3, 4, 6, 8, 12, 16, and 24 h), 500 µL of sample was drained and refilled with fresh buffer. The samples were then analyzed by HPLC [ 37 ].…”

Section: Methodsmentioning

confidence: 99%

“…Homogenate was soaked in methanol under stirring overnight to extract LS. The extract was filtered through 0.45 syringe filter and analyzed by HPLC [ 37 ].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Thiolated Chitosan Microneedle Patch of Levosulpiride from Fabrication, Characterization to Bioavailability Enhancement Approach

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this sense, changes in the management of this fruit are necessary to accompany the dynamics of economic demands, with minimal environmental impacts [ 8 , 9 , 10 ]. Because avocado solid waste retains useful bioactive natural compounds, this residue has been targeted by several interesting studies to recover phytochemicals of industrial interest [ 11 , 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Phytochemicals of Avocado Residues as Potential Acetylcholinesterase Inhibitors, Antioxidants, and Neuroprotective Agents

et al. 2022

View full text Add to dashboard Cite

Avocado (Persea americana) is a widely consumed fruit and a rich source of nutrients and phytochemicals. Its industrial processing generates peels and seeds which represent 30% of the fruit. Environmental issues related to these wastes are rapidly increasing and likely to double, according to expected avocado production. Therefore, this work aimed to evaluate the potential of hexane and ethanolic peel (PEL-H, PEL-ET) and seed (SED-H, SED-ET) extracts from avocado as sources of neuroprotective compounds. Minerals, total phenol (TPC), total flavonoid (TF), and lipid contents were determined by absorption spectroscopy and gas chromatography. In addition, phytochemicals were putatively identified by paper spray mass spectrometry (PSMS). The extracts were good sources of Ca, Mg, Fe, Zn, ω-6 linoleic acid, and flavonoids. Moreover, fifty-five metabolites were detected in the extracts, consisting mainly of phenolic acids, flavonoids, and alkaloids. The in vitro antioxidant capacity (FRAP and DPPH), acetylcholinesterase inhibition, and in vivo neuroprotective capacity were evaluated. PEL-ET was the best acetylcholinesterase inhibitor, with no significant difference (p > 0.05) compared to the control eserine, and it showed neither preventive nor regenerative effect in the neuroprotection assay. SED-ET demonstrated a significant protective effect compared to the control, suggesting neuroprotection against rotenone-induced neurological damage.

show abstract

Harnessing Therapeutic Potentials of Biochanin A in Neurological Disorders: Pharmacokinetic and Pharmacodynamic Overview

Kumar,

Angelopoulou,

Pyrgelis

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

Biochanin A, an isoflavone flavonoid with estrogenic activity, is naturally found in red clover and other legumes. It possesses a wide range of pharmacological properties, including antioxidant, anti‐inflammatory, anti‐apoptotic, neuroprotective, and anticancer effects. In recent years, a growing body of pre‐clinical research has focused on exploring the therapeutic potential of biochanin A in various neurological disorders, such as Alzheimer's and Parkinson's disease, multiple sclerosis, epilepsy, ischemic brain injury, gliomas, and neurotoxicity. This comprehensive review aims to shed light on the underlying molecular mechanisms that contribute to the neuroprotective role of biochanin A based on previous pre‐clinical studies. Furthermore, it provides a detailed overview of the protective effects of biochanin A in diverse neurological disorders. The review also addresses the limitations associated with biochanin A administration and discusses different approaches employed to overcome these challenges. Finally, it highlights the future opportunities for translating biochanin A from pre‐clinical research to clinical studies while also considering its commercial viability as a dietary supplement or a potential treatment for various diseases.

show abstract

Genistein: A Potential Natural Lead Molecule for New Drug Design and Development for Treating Memory Impairment

Cited by 24 publications

References 60 publications

Thiolated Chitosan Microneedle Patch of Levosulpiride from Fabrication, Characterization to Bioavailability Enhancement Approach

Thiolated Chitosan Microneedle Patch of Levosulpiride from Fabrication, Characterization to Bioavailability Enhancement Approach

Phytochemicals of Avocado Residues as Potential Acetylcholinesterase Inhibitors, Antioxidants, and Neuroprotective Agents

Harnessing Therapeutic Potentials of Biochanin A in Neurological Disorders: Pharmacokinetic and Pharmacodynamic Overview

Contact Info

Product

Resources

About